The p542 Gene Encodes an Autoantigen that Cross-Reacts with EBNA-1 of the Epstein Barr Virus and which may be a Heterogeneous Nuclear Ribonucleoprotein

Rhodes, Gary; Valbracht, Jean; Nguyen, Minh-Duc; Vaughan, John H.

doi:10.1006/jaut.1997.9996

Cited by 27 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RALY was originally identified as an autoantigen that cross-reacts with EBNA-1 of the Epstein-Barr virus in infectious mononucleosis (Rhodes et al 1997). It too is a member of the hnRNP superfamily, and is also known as hnRNP C-like 2.…”

Section: Discussionmentioning

confidence: 99%

Mechanisms of activation and repression by the alternative splicing factors RBFOX1/2

Sun¹,

Zuo²,

Fregoso³

et al. 2011

RNA

View full text Add to dashboard Cite

RBFOX1 and RBFOX2 are alternative splicing factors that are predominantly expressed in the brain and skeletal muscle. They specifically bind the RNA element UGCAUG, and regulate alternative splicing positively or negatively in a position-dependent manner. The molecular basis for the position dependence of these and other splicing factors on alternative splicing of their targets is not known. We explored the mechanisms of RBFOX splicing activation and repression using an MS2-tethering assay. We found that the Ala/Tyr/Gly-rich C-terminal domain is sufficient for exon activation when tethered to the downstream intron, whereas both the C-terminal domain and the central RRM are required for exon repression when tethered to the upstream intron. Using immunoprecipitation and mass spectrometry, we identified hnRNP H1, RALY, and TFG as proteins that specifically interact with the C-terminal domain of RBFOX1 and RBFOX2. RNA interference experiments showed that hnRNP H1 and TFG modulate the splicing activity of RBFOX1/2, whereas RALY had no effect. However, TFG is localized in the cytoplasm, and likely modulates alternative splicing indirectly.

show abstract

Section: Discussionmentioning

confidence: 99%

Mechanisms of activation and repression by the alternative splicing factors RBFOX1/2

Sun¹,

Zuo²,

Fregoso³

et al. 2011

RNA

View full text Add to dashboard Cite

show abstract

“…For an isolated EBNA-1 protein (p72), no native antigens are available; accordingly, the DiaSorin assay employs a synthetic peptide and the manufacturers of the other three use recombinant antigens. In contrast to the Novitec and Virotech assays, which make use of the full-length EBNA-1 antigen, the Biotest assay employs a protein lacking the glycine-alanine repeat sequence of EBNA-1 that is known to occasionally cross-react with cellular proteins (11,13). Nevertheless, the number of false-positive EBNA-1 IgG results obtained with the Biotest assay was not lower than that obtained with the Novitec or Virotech assay.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Four Commercially Available Epstein-Barr Virus Enzyme Immunoassays with an Immunofluorescence Assay as the Reference Method

Гартнер

Hess

Bandt³

et al. 2003

Clin Vaccine Immunol

View full text Add to dashboard Cite

Four commercially available enzyme immunoassays (EIAs) (Novitec, Biotest, Virotech, and DiaSorin) were evaluated, with an indirect immunofluorescence assay as the reference method, for Epstein-Barr virus (EBV) VCA (viral capsid antigen) immunoglobulin G (IgG), VCA IgM, or EBNA (EBV nuclear antigen) IgG at three different locations (Homburg, Stuttgart, and Dresden). Serum samples from 66 immunocompetent patients with infectious mononucleosis, 73 patients without prior EBV infection, and 96 patients with past EBV infections and 29 serum samples with possible cross-reactions to other herpesviruses were included. In addition, 25 samples from an extensively pretested panel that is commercially available (Boston Biomedica) were tested. Each sample was tested at only one location. The four EIAs varied considerably in performance. When analyzing for EBV diagnosis, the Novitec assay performed the best, with 4.9% discrepant diagnoses, followed by the Biotest, Virotech, and DiaSorin assays, with 6.8, 11.7, and 14.0% discrepant diagnoses, respectively. On the basis of single-parameter analysis, the Novitec assay also showed the lowest number of discrepant results, with 3.5%, compared with the Virotech, Biotest, and DiaSorin assays, which produced 5.4, 6.4, and 8.6% discrepant results, respectively. VCA assays using affinity-purified native antigens performed better than assays with recombinant or synthetic antigens. The synthetic EBNA-1s showed the lowest concordance with the reference compared to recombinant p72. Commercially available EBV EIAs differed considerably in performance; however, some proved to be reliable and convenient alternatives to the indirect immunofluorescence assay for routine diagnostics. Native antigens, rather than synthetic peptides, are favored for EBV serology testing.

show abstract

“…EBV DNA has been detected in the lungs of SSc patients (21). It has been observed that an antibody against hnRNP autoantigen called p542 may develop in mononucleosis, and IgG anti-p542 has been discovered in SSc (22). In these patients, autoantibodies against a 60-62-kDa cellular protein, which cross-reacts with the glycine/alanine repeat in EBNA-1, may have been detected (19).…”

Section: Discussionmentioning

confidence: 99%

The prevalence of infectious agents in patients with systemic sclerosis

BİLGİN>¹,

KOCABAŞ²,

KEŞLİ³

2015

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Systemic sclerosis (SSc) is an autoimmune disease characterized by microvascular injury, excessive extracellular matrix deposition, and fibrosis in the skin and internal organs. Bacterial and viral infectious agents have been suspected to be contributing factors in the development and progression of the pathologic features of SSc. Materials and methods:In this study, 30 SSc patients who were admitted to the rheumatology unit of the Konya Training and Research Hospital and 30 healthy controls were included. The presence of 9 different antibodies (IgM and IgG) against Helicobacter pylori, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and parvovirus B19 were investigated in sera samples obtained from the 60 participants using an enzyme-linked immunosorbent assay method. The characteristics of current and past infections with H. pylori, CMV, EBV, and parvovirus B19 were evaluated by determining the seropositivity of the tested bacterial and viral agents. Results:The prevalences of H. pylori, CMV, EBV, and parvovirus B19 were determined to be higher in patients with SSc than in the control group. Conclusion:SSc is associated with a higher rate of certain infections, which deserves further investigation in order to assess the role of infections in disease etiology/pathogenesis.

show abstract

The p542 Gene Encodes an Autoantigen that Cross-Reacts with EBNA-1 of the Epstein Barr Virus and which may be a Heterogeneous Nuclear Ribonucleoprotein

Cited by 27 publications

References 20 publications

Mechanisms of activation and repression by the alternative splicing factors RBFOX1/2

Mechanisms of activation and repression by the alternative splicing factors RBFOX1/2

Evaluation of Four Commercially Available Epstein-Barr Virus Enzyme Immunoassays with an Immunofluorescence Assay as the Reference Method

The prevalence of infectious agents in patients with systemic sclerosis

Contact Info

Product

Resources

About